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Background
Cancer anorexia-cachexia is a frequent, debilitating and
life-threatening condition in which altered metabolism
and reduced food intake contribute to weight loss
(mainly due to lean body mass [LBM] loss), which can-
not be reverted by conventional nutritional support.
Safe/effective treatments for cancer cachexia remain an
unmet need. The hunger hormone ghrelin has been
shown to activate key pathways in the regulation of
body composition. Anamorelin (ANAM) is a novel,
selective, oral ghrelin receptor agonist with appetite-
enhancing and anabolic activity. Anamorelin is currently
being investigated in phase III studies for the treatment
of anorexia-cachexia in advanced non-small cell lung
cancer (also known as the ROMANA program).
Material and Methods
Eighty-two patients with advanced cancer, ECOG perfor-
mance score ≤ 2 and weight loss 5% within prior 6 months
were treated with placebo (n=36) or 50mg anamorelin
(n=38) once daily for 12 weeks. Body composition by
DXA, handgrip strength (HGS) and Quality of Life (QoL;
ASAS scale) were assessed at baseline, 4, 8 and 12 weeks.
Solid tumors represented prevalent malignancy (>93%)
with no difference in cancer types between treatment
groups.
Results
Treatment with anamorelin for 12 weeks significantly
increased total body mass (TBM) and LBM. Increases in
LBM and TBM in anamorelin-treated patients were
strongly correlated (r2=0.7249, p< 0.0001). Anamorelin
treatment improvements in HGS and QoL were previously
presented [1]. Anamorelin was well tolerated, and types
and prevalence of AEs were similar between treatment
arms.
Conclusion
Decreased body weight and LBM are poor prognostic fac-
tors in cancer cachexia patients. This study demonstrates
that 50mg anamorelin treatment for 12 weeks significantly
increased LBM, which largely contributed to the increases
in total body mass. Together with its appetite-enhancing
activity, these results support the further development of
anamorelin in treating cancer anorexia-cachexia.
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